The Wall Street Resource

A developer of Generation IV nuclear plants powered by its Integral Molten Salt Reactor (IMSR) technology, delivering innovation in efficiency, cost, versatility and functionality. The IMSR Plant is small, modular and designed to supply low-cost, reliable, high-temperature heat and electricity for industrial applications, including data centers, and chemical and petrochemical supply. By extending nuclear energy beyond power markets, IMSR Plant supports clean firm heat and power, self-reliance, grid reliability and economic growth. Using proven U.S. molten salt technology and inexpensive, readily available standard-assay low-enriched uranium fuel, Terrestrial Energy is working with regulators, suppliers, customers and industrial partners to commission a fleet of IMSR plants across the U.S. in the 2030s

Nextech3D.ai is an AI-first technology company focused on transforming how enterprises engage with customers through event technology, immersive digital experiences, and artificial intelligence-powered solutions. Through its portfolio of businesses, including EventDex, Map D, and KraftyLabs, the Company serves enterprise customers seeking innovative solutions that drive engagement, efficiency, and measurable results.

A computing infrastructure company operating advanced computing equipment and expanding into AI infrastructure. The Company's strategy is built on three principles: lead with power by acquiring operating sites where power is already flowing; build for AI workloads by converting that capacity into AI-ready colocation where the customer brings the compute and runs what they need; and scale with discipline by deploying conversion capital site by site, against signed contracts and operational readiness.

A clinical-stage biotechnology company developing proprietary treatments focused on the biology and potential therapeutic advantages of regulatory T cells (“Tregs”) to target systemic inflammation and neuroinflammation. Dysfunctional Tregs underlie numerous conditions, including neurodegenerative, metabolic, and autoimmune diseases. This cellular dysfunction may lead to sustained inflammation and oxidative stress resulting in lack of homeostasis of the immune system.

Coya’s investigational product candidate pipeline leverages multiple therapeutic modalities aimed at restoring the anti-inflammatory and immunomodulatory functions of Tregs. Coya’s therapeutic platforms include Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.

An innovative biopharmaceutical company dedicated to elevating treatment effectiveness, right where care begins. The Company develops long-acting, controlled-release drugs designed to deliver therapy precisely at the site of care, addressing critical unmet medical needs across a wide and diverse pipeline spanning surgical care, metabolic diseases, and beyond. PolyPid's lead product, D-PLEX₁₀₀, successfully met its primary and all key secondary endpoints in the landmark Phase 3 SHIELD II trial for the prevention of surgical site infections.

A public safety technology company focused on developing patented, less lethal solutions designed to preserve life, reduce risk and protect individuals in high-stress situations. A system intended to bridge the capability gap between traditional less-lethal tools and lethal force by providing a controlled force option designed to de-escalate critical incidents. The Company is about to introduce a consumer-focused version of its technology to the U.S. commercial market under The Home Defense™ brand. This consumer product is intended to provide individuals with an additional, less-lethal self-defense option designed to establish intent, reduce potential liability, and help mitigate the risk of severe or fatal outcomes prior to the use of lethal force.

A leading developer and provider of innovative display, Optical Interconnect devices and application-specific optical solutions sold as critical components and subassemblies for defense, enterprise, professional and consumer products.

Kopin’s portfolio includes microdisplays, display modules, eyepiece assemblies, image projection modules and vehicle mounted and head-mounted display systems that incorporate ultra-small high-resolution Active Matrix Liquid Crystal displays (AMLCD), Ferroelectric Liquid Crystal on Silicon (FLCoS) displays, MicroLED displays (µLED) and Organic Light Emitting Diode (OLED) displays, a variety of optics and low-power ASICs and optical interconnect devices for AI data centers.

Birchtech Corp. (NYSE American: BCHT) (TSX: BCHT) is a provider of specialty activated carbon technologies, delivering innovative solutions for air and water purification to support a cleaner, more sustainable future. The Company provides patented SEA® sorbent technologies for mercury emissions capture for the coal-fired utility sector and is developing disruptive water purification technologies with a specialization on forever chemicals such as PFAS and PFOS. Backed by a strong intellectual property portfolio and a team of activated carbon experts, Birchtech provides cleaner air to North American communities and is applying this expertise to an innovative approach in water purification.

A leading manufacturer of full-body virtual reality systems for consumer, enterprise, and defense markets. The company’s premier portfolio of “Omni” omni-directional treadmills enables players to walk and run in 360 degrees inside video games and other virtual reality applications. With a commitment to innovation, Virtuix continues to push the boundaries of XR and AI, delivering immersive experiences to users worldwide.

A Canadian Good Manufacturing Practices ("GMP") compliant, pharmaceutical drug manufacturer licensed by Health Canada for the handling of controlled substances and GMP production. From two 10,000-square-foot facilities in British Columbia and operating under a Drug Establishment License from Health Canada, Optimi supplies active pharmaceutical ingredients and finished dosage forms to regulated channels, with products currently in market for prescription use in Australia via the Authorized Prescriber Scheme and accessible in Canada through the Special Access Program.